We discuss study recommendations on the effects of sGC modulators and PDE-5-inhibitors in liver diseases such as modulation of the NO-cGMP pathway for treatment of portal hypertension [33], reversal of fibrosis/cirrhosis, therapy of hepatic encephalopathy using PDE-5-inhibitors, and determination of serum/plasma cGMP levels as an indicator of portal hypertension. The gene discussed is PDE5A; the disease is fibrosis.